Welcome to our dedicated page for MARIMED SEC filings (Ticker: MRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MARIMED's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MARIMED's regulatory disclosures and financial reporting.
MARIMED INC. President and CEO Jon R. Levine reported on July 15, 2026 the vesting and settlement of 30,625 restricted stock units into common stock and a related 10,612-share tax-withholding disposition. Following these transactions, he directly holds 21,358,631 common shares, with 91,875 RSUs remaining under the grant that will vest in three equal installments on October 15, 2026, January 15, 2027 and April 15, 2027. An additional 6,684,640 shares are held in a family trust for his spouse and children, for which he disclaims beneficial ownership.
MariMed Inc. reports that COO Timothy Shaw exercised 42,656 RSUs into common stock and had 14,781 shares withheld to satisfy tax obligations related to the vesting. After these transactions, he holds 9,412,123 shares directly and 127,969 RSUs, plus 2,000,000 shares held in an irrevocable family trust for his children, for which he disclaims beneficial ownership.
MARIMED INC. Chief Commercial Officer Ryan Crandall reported RSU vesting and related tax withholding on July 15, 2026. He converted 32,813 Restricted Stock Units into common stock and had 11,370 shares withheld to cover taxes, leaving 1,124,246 common shares and 98,437 RSUs held directly. Remaining RSUs vest in three equal installments through April 15, 2027, and the transactions were not made under a Rule 10b5-1 plan.
MariMed Inc. chief financial officer Mario Pinho reported equity-compensation transactions dated July 15, 2026. He exercised 88,276 restricted stock units into common stock and had 30,589 common shares withheld at $0.0662 per share to satisfy tax withholding obligations. After these transactions, he directly holds 335,172 common shares and continues to hold unvested RSUs from grants dated July 15, 2024 and April 15, 2026 that vest in installments through April 15, 2027.
MARIMED INC. director Eva M.D. Selhub received an equity award of 173,077 Restricted Stock Units on July 15, 2026 as part of her board fees. The RSUs vested immediately and converted one-for-one into 173,077 common shares, after which she directly owns 730,748 common shares.
MARIMED INC. director Allen David R received 192,308 Restricted Stock Units on July 15, 2026 in lieu of a portion of his board fees. The RSUs vested upon grant and converted one-for-one into 192,308 shares of common stock at no cash exercise price, increasing his direct holdings to 743,452 shares. No RSUs from this award remain outstanding.
MariMed Inc. director Edward J. Gildea received 192,308 restricted stock units on July 15, 2026 as part of his board fees, granted in lieu of cash. These RSUs vested immediately and converted one-for-one into 192,308 common shares at no cash cost, increasing his direct holdings to 1,172,516 shares and leaving no RSUs outstanding from this award.
MariMed Inc. reports that Chief Commercial Officer Ryan Crandall exercised 250,000 Restricted Stock Units into common stock on June 15, 2026, from a December 15, 2025 RSU grant. To cover tax obligations, 86,626 shares were withheld at $0.069 per share. Following these transactions, he directly holds 1,102,803 common shares, with remaining RSUs under this grant scheduled to vest in equal installments on December 15, 2026, June 15, 2027 and December 15, 2027.
MARIMED INC. director Eva Selhub, M.D. exercised 75,000 Restricted Stock Units (RSUs) into the same number of shares of common stock. This was recorded as a derivative exercise, not an open‑market purchase or sale. After the transaction, she directly holds 557,671 shares of common stock. The RSUs converted to common stock on a one-for-one basis and this grant, originally awarded on June 12, 2025, is now fully exhausted under its award agreement.
MariMed Inc. director Edward J. Gildea exercised restricted stock units into common shares. On June 12, 2026, 75,000 RSUs converted into 75,000 shares of common stock on a one-for-one basis at no cash exercise price. This exhausted the June 12, 2025 RSU grant, and Gildea now holds 980,208 common shares directly.